1st International AIDS Conference Atlanta, Georgia, U.S.A. - April 14-17, 1985

Int Conf AIDS 1985 Apr 14-17; 1:21 (abstract no. S1D)

Willy Rozenbaum, D Dormont, E Vilmer, B Spire, F Barré & L Montagnier & J-C Chepmann
La Pitie-Salpêtriere Hospital, Research Center of the Army Health Services, and Pasteur Institute, Paris

Patients with AIDS or related syndrome were selected by the detection of antibodies to Lymphadenopathy Associated Virus (LAV) and by the isolation of LAV from cultured peripheral blood cells. Two types of treatment with Tungsto-antimoniate (HPA33) were scheduled: IV bolus or IV infusion for 3 hrs per day during 15 days. In some patients (2 out of 4), LAV was not isolated one month after the end of treatment, even after cocultivation indicating that the viral amount in the cells was below our methods of detection. One AIDS hemophiliac patient, one year after the end of HPAp3 therapy did not present any more opportunistic infections, despite persistence of low absolute number of T4+ cells. Parallely with an incomplete LAV inhibition, another patient stabilized his mucosal evolutive Kaposi sarcoma without regression (6 months outcome). HPA23 therapy was associated with a reversible thrombocytopenia and a moderate change in hepatic transaminase (2 × normal values). No renal toxicity was observed. Such promising clinical observations are in the way to be confirmed by the treatment of new consenting PGL patients, now under evaluation.

850414
S1D

Copyright © 1985 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.